Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular diseases

This page shows the latest cardiovascular diseases news and features for those working in and with pharma, biotech and healthcare.

Alexion targets RNAi with $637m Dicerna deal

Alexion targets RNAi with $637m Dicerna deal

Alexion has signed a deal with RNAi specialists Dicerna to discover therapies for complement-mediated diseases. ... The drug technology platform produces compounds that inhibit complement activation, and it can be applied across multiple therapeutic areas

Latest news

More from news
Approximately 5 fully matching, plus 90 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    He says the company is “very confident”of sustaining growth in China, and says its broad portfolio of medicines across oncology, respiratory and cardiovascular, metabolic and renal will help it achieve ... diseases, cardiovascular diseases, metabolic

  • Finding the patient voice Finding the patient voice

    rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.

  • Deal Watch December 2016 Deal Watch December 2016

    1, 850. Bicycle (UK). AstraZeneca (UK). Licence collaboration. Bicycle platform: small molecules with antibody specificity for targets in respiratory, cardiovascular and metabolic diseases. ... 320. Evotec (Germany). Celgene (US). Discovery collaboration.

  • A healthy challenge A healthy challenge

    Vytenis told PME he is “ very concerned” about the rising burden of chronic non-communicable diseases, such as cardiovascular diseases, cancer and type 2 diabetes. “ ... The risk of developing these diseases is very much increased due to some of

  • Opening up innovation Opening up innovation

    For GlaxoSmithKline its pharma open innovation efforts began with diseases of the developing world, such as malaria - where it offered researchers free access to a 'virtual library' of tens of thousands ... With over 1, 000 potential products being

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    Prior to this, Dr Lee was therapeutic area head for cardiovascular, metabolic, respiratory and infectious disease programmes at Genentech. ... Meanwhile, Dr Tripuraneni (pictured left) brings over 10 years of medical affairs expertise in a variety of

  • Cardio3 BioSciences appoints Warren Sherman chief medical officer Cardio3 BioSciences appoints Warren Sherman chief medical officer

    therapy and other treatments for cardiovascular diseases.”. ... for the further development of Cardio3 BioSciences' future projects in regenerative therapies and cardiovascular diseases.”.

  • Pfizer appoints diabetes expert Morris Birnbaum Pfizer appoints diabetes expert Morris Birnbaum

    Pfizer appoints diabetes expert Morris Birnbaum. He takes up post as chief scientific officer for cardiovascular and metabolic diseases. ... Pfizer has appointed prominent academic Dr Morris Birnbaum as chief scientific officer for its research into

  • INC Research appoints Dr Martin Sullivan INC Research appoints Dr Martin Sullivan

    INC Research has appointed Dr Martin Sullivan as its new executive director for cardiovascular medicine. ... Sally Osmond, general manager of cardiovascular and endocrinology clinical development at INC Research, said: "The prevalence of cardiovascular

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics